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We compared the expression of MYH7-alleles in non-HCM 
donors and in HCM-patients with different MYH7-missense 
mutations. In the HCM-patients, we identified imbalanced as 
well as equal expression of both alleles. Also at the protein 
level, allelic imbalance was determined. Most interestingly, 
we also discovered allelic imbalance and balance in non-
HCM donors. Our findings therefore strongly indicate that 
apart from mutation-specific mechanisms, also non-HCM 
associated allelic-mRNA expression regulation may account 
for the allelic imbalance of the MYH7 gene in HCM-patients. 
Since the relative amount of mutant mRNA and protein or 
the extent of allelic imbalance has been associated with the 
severity of HCM, individual analysis of the MYH7-allelic 
expression may provide valuable information for the prog-
nosis of each patient.
Keywords Hypertrophic cardiomyopathy · Allelic 
imbalance · MYH7 · Beta-myosin
Introduction
HCM is the most common disease of the heart with an inci-
dence of 1:500 (Maron et al. 2012). Mutations in different 
sarcomeric genes have been shown to account for most of the 
HCM-cases (Cecconi et al. 2016; Maron et al. 2012). One 
of the most affected genes is MYH7 (Marsiglia and Pereira 
2014), encoding for the β-myosin heavy chain (β-MyHC), a 
central player in cardiac and slow muscle contraction.
Numerous mutations in the MYH7-gene have been 
associated with HCM (Walsh et al. 2009). Since muta-
tions in the MYH7-gene are mostly missense mutations, 
a poison peptide effect has been postulated for the mutant 
proteins. With respect to disease, benign or malignant 
phenotypes were assigned. This assignment was then 
Abstract HCM, the most common inherited cardiac dis-
ease, is mainly caused by mutations in sarcomeric genes. 
More than a third of the patients are heterozygous for muta-
tions in the MYH7 gene encoding for the β-myosin heavy 
chain. In HCM-patients, expression of the mutant and the 
wildtype allele can be unequal, thus leading to fractions 
of mutant and wildtype mRNA and protein which deviate 
from 1:1. This so-called allelic imbalance was detected in 
whole tissue samples but also in individual cells. There is 
evidence that the severity of HCM not only depends on 
the functional effect of the mutation itself, but also on the 
fraction of mutant protein in the myocardial tissue. Allelic 
imbalance has been shown to occur in a broad range of 
genes. Therefore, we aimed to examine whether the MYH7-
alleles are intrinsically expressed imbalanced or whether 
the allelic imbalance is solely associated with the disease. 
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transmitted to the causative mutations, classifying muta-
tions as benign or malignant (Maron 2002). However, 
this was contrasted by the finding that the severity of the 
disease can vary even between patients with the same 
mutation (Maron 2002; Maron et al. 2012). Therefore 
additional environmental and genetic factors must influ-
ence the disease phenotype (Lopes et al. 2013).
Unequal expression of the two alleles of a gene (allelic 
imbalance) has been reported for a broad range of genes 
and tissues and the imbalanced expression of disease 
associated variants can influence the progression of dif-
ferent diseases (Pastinen 2010). Also for HCM it was 
shown that the relative abundance of mutant and wildtype 
mRNA and protein varies between the HCM-mutations 
(Di Domenico et al. 2012; Helms et al. 2014; Tripathi 
et al. 2011; Witjas-Paalberends et al. 2013) and the ratio 
of mutant/wildtype β-MyHC seems to be associated with 
disease severity (Jiang et al. 2013; Tripathi et al. 2011). 
In addition to this tissue-level allelic imbalance, we have 
shown recently that the relative fraction of mutant vs. 
wildtype mRNA is also variable from cell to cell in the 
myocardium of HCM-patients (Kraft et al. 2016). We have 
evidence that this cell-to-cell allelic imbalance is caused 
by an independent and stochastic ON- and OFF-switch-
ing of the mutant and the wildtype MYH7 allele in each 
individual cell. In principle, such a stochastic expression 
should result in nearly equal fractions of mRNA from 
both alleles at the tissue level. Yet, on average we found 
the same deviation from a 1:1 relation of mutant and 
wildtype mRNA for all analyzed single cells as it was 
determined at the tissue level for the same patients (Kraft 
et al. 2016; Tripathi et al. 2011). Therefore, factors addi-
tional to the stochastic ON- and OFF-switch of the alleles 
must induce the allelic imbalance at the tissue level. The 
regulatory mechanisms of allelic expression imbalance 
encompass variants in different cis-regulatory elements 
such as RNA-stability and turnover, transcription factor 
binding or splicing regulators but also epigenetic regula-
tors such as DNA methylation (Bjornsson et al. 2008; 
Milani et al. 2009). Therefore, the allelic imbalance of the 
MYH7 gene in HCM may either be affected by intrinsic 
sequence variations in regulatory regions of the HCM-
associated alleles or be directly altered by the mutations.
We hypothesize that if not only the HCM-mutation 
but also intrinsic, non-HCM-related expression regulat-
ing factors on the alleles hold responsible for the MYH7 
allelic expression, allelic imbalance will also be detected 
in non-HCM controls. To address this question we exam-
ined the relative expression of the MYH7 alleles based 
on single base substitutions in 11 non-HCM donors and 
in ten HCM-patients with heterozygous mutations in the 
MYH7-gene.
Materials and methods
RNA extraction and RT‑qPCR
Muscle tissue of Musculus soleus and myocardial tissues 
were flash frozen directly after excision and stored under 
liquid nitrogen. RNA was extracted using the PeqGold Total 
RNA Kit (PeqLab, Erlangen, Germany) according to the 
supplier’s instructions. Total RNA was subjected to cDNA-
synthesis using 1× reaction buffer, 0.125 mM dNTPs each, 
0.4 µM MYH7 specific primers (Table 1), 1 U/µl RNase 
inhibitor (RiboSafe, Bioline, Luckenwalde, Germany), and 
5 U/µl reverse transcriptase (Tetro RT, Bioline) and 1 µl 
RNA for 1 h at 42 °C. Unless stated otherwise in Table 1, 
for amplification 1 µl cDNA was mixed with 1x reaction 
buffer, 0.5 mM  MgCl2, 0.2 mM of each dNTP, 0.2 µM of 
both forward and reverse Primers (Table 1), and 0.04 U/µl 
HotStarTaq (Qiagen, Hilden, Germany). Initial activation 
was performed for 15 min at 95 °C. Subsequently 45 cycles 
were applied with 95 °C for 30 s, 64 °C for 30 s, and 72 °C 
for 30 s. The final elongation was performed at 72 °C for 
2 min. To minimize heteroduplexes a reconditioning PCR 
was performed. 2.5 µl PCR product were transferred to a 
final volume of 25 µl respective PCR reaction mix, and 
the respective PCR protocol was run for three successive 
cycles (Thompson et al. 2002).
Allele specific restriction digest
12.5 µl of the reconditioned PCR products were treated with 
respective restriction enzymes (Table 1) in a final volume 
of 15 µl for at least 3 h to yield the allele specific fragments 
(Table 1). The fragments were separated on 3% sieving 
agarose gels stained with ethidiumbromide and mutant vs. 
wildtype MYH7 mRNA was quantified as described previ-
ously in detail (Tripathi et al. 2011). In brief, the restric-
tion fragments were analysed densitometrically using the 
TotalLab (Newcastle upon Tyne, Great Britain) and Origin 
(OriginLab, Northampton, MA, USA) software, yielding the 
integrated optical density (IOD) of each band. The IOD was 
normalized against the number of base pairs. The fraction of 
mutant per wildtype MYH7 mRNA was calculated from the 
IOD/bp values of the respective bands.
Relative quantification of mutant and wildtype myosin
The quantification of mutant and wildtype β-MyHC protein 
was performed as described previously in detail (Becker 
et al. 2007). In brief, for each mutation a specific set of 
isotope labelled peptides  (Table 1) was spiked in equal 
quantities to extracted myosin from tissue samples of the 
HCM-patients. The mixture was digested using trypsin 
(A200V), Lys-C (G716R) or Asp-N (G741R) and subjected 
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to LC/ESI-based analysis of the ratio of WT- and mutant-
specific peptides in the samples. The isotope labelled pep-
tides were used as internal standards for the quantification 
to correct for sequence specific ionization. The assays were 
established using mutant and wildtype specific synthetic 
peptides (Table 1).
Statistics
For statistical analysis of the deviation from the 50:50 ratio, 
we used one way ANOVA test. We compared the fractions 
of all quantification experiments per mutation or variant, 
respectively, with the theoretically expected 50%. Analysis 
was performed using the GraphPad Prism software, signifi-
cance was assigned for p < 0.0001.
Ethics statement
Informed consent was obtained from all individuals accord-
ing to approved Ethics Committee protocols of the institu-
tions involved. The study was approved by the Ethics Com-
mittee of Hannover Medical School (no. 2276-2014). The 
investigations conformed to the principles of the Declaration 
of Helsinki (1997).
Results
Patients and non‑HCM donor genetics
We analyzed the allelic expression of the MYH7 gene in 
21 individuals based on single base substitutions (Table 2). 
We analyzed flash frozen tissue from slow skeletal muscle 
(M. soleus) from one male HCM-patient with the mutation 
R453C and one male and two female patients with the muta-
tion G741R. In addition, left ventricular/interventricular sep-
tum tissue from one HCM-patient each with the mutation 
A200V, V606M, G716R, R719W, D752N, and T1377M 
was analyzed. Slow skeletal muscle fibers express mainly 
the β-myosin isoform and as we have shown previously, the 
allelic imbalance of the MYH7 gene is comparable in slow 
skeletal muscle and heart tissue (Tripathi et al. 2011). The 
three patients with the mutation G741R were related, how-
ever showed distinct progression of HCM at biopsy rang-
ing from asymptomatic (G741R-1, age at biopsy 45), dysp-
nea on effort (G741R-3, age at biopsy 39) to severe heart 
failure (G741R-2, age at biopsy 55). Exemplary analysis 
revealed that the patients A200V, R453C, G716R, G741R-
1, G741R-2 and G741R-3 showed no variants in the in the 5′ 
and 3′-UTR. The patients G741R-1, G741R-2 and G741R-3 
were further analyzed for SNPs in the promotor region and 
also showed no variants.
The MYH7-variants R453C and V606M (Watkins et al. 
1992), G716R and R719W (Anan et al. 1994), and G741R 
(Fananapazir et al. 1993) have been previously described as 
disease causing and are listed as “pathogenic” in the Clin-
Var database. In addition, they are reported with a very low 
allele frequency or are even not present in the Exac or Gno-
mAD databases and at least three out of four in silico predic-
tion softwares report the variants as pathogenic (Table 3). 
Therefore, these HCM-variants strongly fulfill the criteria 
of pathogenicity according to the ACMG guidelines (Rich-
ards et al. 2015). The mutation T1377M is listed as “likely 
pathogenic” in ClinVar, it has been described previously as 
Table 2  Relative expression of the MYH7 alleles in HCM-patients 
and non-HCM donors
*Significant deviation from 50% of equal allelic expression 
(p > 0.0001)
Variant Individual Gender Tissue Fraction of mutant allele 
(mean ± SEM)
mRNA Protein
A200V Female Septum 48.3 ± 1.9 49.1 ± 0.9
R453C Male Soleus 37.0 ± 1.0*
V606M Male Septum 37.5 ± 0.8*
G716R Male Left ven-
tricle
88.6 ± 0.2* 29.9 ± 0.9*
R719W Male Left ven-
tricle
52.2 ± 0.4
G741R 1 Male Soleus 18.8 ± 0.4* 21.4 ± 0.4*
2 Female Soleus 49.4 ± 1.0 26.9 ± 0.6*
3 Female Soleus 44.8 ± 2.9 26.7 ± 0.6*
D752N Male Septum 7.9 ± 0.6*
T1377M Female Septum 52.3 ± 1.1
T63T 1 Male Left ven-
tricle
51.1 ± 0.33
2 Female Left ven-
tricle
49.2 ± 0.97
3 Male Left ven-
tricle
5.5 ± 0.15*
I989I 1 Female Left ven-
tricle
51.2 ± 0.04
2 Female Left ven-
tricle
51.3 ± 0.1
3 Female Left ven-
tricle
53.2 ± 0.1
4 Male Left ven-
tricle
52.6 ± 0.1
A1702A 1 Female Left ven-
tricle
60.2 ± 0.2*
2 Male Left ven-
tricle
60.3 ± 0.7*
3 Female Left ven-
tricle
58.1 ± 0.2*
4 Male Left ven-
tricle
50.1 ± 0.3
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HCM-mutation (Helms et al. 2014) and it is highly seldom 
in the reference population as determined by the GnomAD 
allele frequency of 4.06 × 10− 6. In addition, in silico predic-
tion of pathogenicity by two out of four independent soft-
ware tools suggests a deleterious effect on the mutant protein 
(Table 3). According to the ACMG guidelines (Richards 
et al. 2015) this indicates strongly to a pathogenic effect of 
the T1377M-variant. The variants A200V and D752N are 
not listed in ClinVar. However, the variant alleles are not 
present in the Exac/GnomAD database and both variants 
are predicted to be deleterious for protein function by the 
three in silico analysis tools. In addition, at position 200 
another pathogenic variant has been determined (A200T) 
(Fujino et al. 2013). Taken together, the ACMG guidelines 
(Richards et al. 2015) strongly support a pathogenic effect 
also of these mutations (Table 3). Therefore, we assume that 
all MYH7-variants in the HCM patients as pathogenic under 
the light of current evidence.
In addition, interventricular septum samples from non-
HCM donors were analyzed for single nucleotide poly-
morphisms (SNPs) in the MYH7 gene. We identified three 
donors heterozygous for the SNP T63T (rs2069540), four 
donors heterozygous for the SNP I928I (rs7157716) and 
four donors heterozygous for the SNP A1702A (rs3729830). 
Under the light of current evidence, the variants are not 
pathogenic (Table 3). To our knowledge, the donors were 
Table 3  Pathogenicity of MYH7-variants of the HCM-patients and donors
a Schwarz et al. (2014)
b Adzhubei et al. (2013)
c Capriotti et al. (2006)
d Mi et al. (2016)
e Richards et al. (2015)
Variant Exac/Gno-
mAD allele 
frequency
In silico predictions of pathogenicity ClinVar clas-
sification
ACMG  classificatione Initial 
reference for 
pathogenic 
variant
Mutation 
 tastera
PolyPhen2b PhD-SNPc PANTHERd
A200V Not present Disease 
causing
Probably 
damaging
Disease Neutral No data Pathogenic 
(PS1 + PM2 + PP3)
Pathogenic 
variant at 
same amino 
acid: Fujino 
et al. (2013)
R453C Not present Disease 
causing
Probably 
damaging
Disease Disease Pathogenic Pathogenic (known 
disease causing, 
PS3 + PM2 + PP3)
Watkins et al. 
(1992)
V606M 3.230 × 10−5 Disease 
causing
Probably 
damaging
Neutral Disease Pathogenic Pathogenic (known 
disease caus-
ing + PS3 + PM2 + PP3)
Watkins et al. 
(1992)
G716R Not present Disease 
causing
Probably 
damaging
Disease Disease Pathogenic Pathogenic (known 
disease causing 
PS3 + PM2 + PP3)
Anan et al. 
(1994)
R719W 3.231 × 10−5 Disease 
causing
Probably 
damaging
Disease Disease Pathogenic Pathogenic (known 
disease causing 
PS3 + PM2 + PP3)
Anan et al. 
(1994)
G741R 3.232 × 10−5 Disease 
causing
Probably 
damaging
Disease Neutral Pathogenic Pathogenic (known 
disease causing 
PS3 + PM2 + PP3)
Fananapazir 
et al. (1993)
D752N Not present Disease 
causing
Probably 
damaging
Disease Neutral No data Pathogenic 
(PS2 + PM2 + PP3)
Not described 
previously
T1377M 4.06 × 10−6 Disease 
causing
Probably 
damaging
Neutral Neutral Likely patho-
genic
Pathogenic (known 
disease causing, 
PS2 + PM2 + PP3)
Helms et al. 
(2014)
T63T 0.47960 Polymor-
phism
Not applica-
ble
Not applica-
ble
Not applica-
ble
Benign Benign (BA1)
I989I 0.32119 Polymor-
phism
Not applica-
ble
Not applica-
ble
Not applica-
ble
Benign Benign (BA1)
A1702A 0.10702 Polymor-
phism
Not applica-
ble
Not applica-
ble
Not applica-
ble
Benign Benign (BA1)
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not related to each other. In total five male and six female 
donors were analyzed.
Allelic balance and imbalance of the MYH7 gene 
in HCM‑patients
We have shown previously, that the mutant and wildtype 
MYH7 alleles are expressed imbalanced at the tissue level 
in HCM-patients with different missense mutations in this 
gene. To examine whether this phenomenon can be detected 
for a broader range of MYH7-mutations, we determined the 
ratio of mutant vs. wildtype transcript in samples of slow 
skeletal muscle tissue and cardiac tissue from HCM-patients 
with eight different MYH7-missense mutations.
The analyses were designed as shown previously for 
HCM-associated MYH7-mutations (Tripathi et al. 2011). In 
brief, the PCR amplicons contained a restriction site that 
was either generated or disrupted by the respective base sub-
stitution. The region of interest was PCR-amplified, recondi-
tioning PCR was performed to eliminate potential heterodu-
plexes originating from the end point PCR and subsequently 
subjected to restriction digest. The allele specific restriction 
fragments were separated by agarose gel electrophoresis, 
quantified densitometrically and the respective ratios of 
each allele were calculated. Each analysis was optimized 
and finally validated using defined mixtures of recombinant 
plasmids encoding either for the wildtype or the mutant 
PCR amplicon. Using the finalized protocols, we relatively 
quantified both alleles in the standard plasmid mixtures for 
ratios between 10:90 and 80:20 in at least three independ-
ent experiments (Fig. 1A). For each patient 2–4 independ-
ent RNA extractions were performed and used for at least 
two cDNA-syntheses. The expression of the mutant allele 
was quantified from each cDNA at least in duplicates and 
statistically compared to a theoretical value of 50% reflect-
ing balanced allelic expression (one way ANOVA) (Fig. 1b).
The mutations R435C, V606M, and D752N showed a 
significantly reduced expression of the mutated allele of on 
average 37.0, 37.5 and 7.9%, respectively (Fig. 1b). In the 
patients with the mutations A200V, R719W, and T1377M 
both alleles were expressed at a similar ratio of 48.3, 52.2, 
and 52.3%, respectively. The mutation G716R showed a high 
expression of the mutant allele with 88.6% (Table 2).
Interestingly, in skeletal muscle tissue from three related 
patients with the mutation G741R we found a varying 
expression pattern. Whereas one patient (G741R-1) showed 
a significantly reduced expression of the mutated allele of 
18.8%, both other patients (G741R-2 and G741R-3) showed 
equal expression of both alleles of 45.6 and 46.6% of the 
mutant allele (Fig. 1b; Table 2). To test for differences 
between the G741R patients we compared SNPs in the pro-
motor region and in exons and flanking intron sequences. 
No variant was identified in the promotor region or the 3′ 
UTR. However, the patients showed different exonic SNPs 
(Table 4).
However, at the protein level the difference between 
patients with the mutation G741R was no longer detect-
able. The myocardial tissue of the three patients contained 
21.4, 26.9, and 26.7%, respectively, of the mutant β-MyHC 
protein (Table 2). Also the patient with mutation G716R 
showed different levels of mutant mRNA and protein. At the 
mRNA level the mutant allele was predominant with 89%, 
while at the protein level only 29.9% mutant myosin was 
found. The patient with mutation A200V in contrast showed 
comparable levels of mutant mRNA and protein.
Fig. 1  Relative quantification of mutant and wildtype MYH7-mRNA 
in HCM-patients. a Defined mixtures of synthetic plasmids encoding 
for the wildtype and the respective mutated sequences were ampli-
fied by quantitative PCR and quantified densitometrically from allele 
specific restriction digests. Quantifications were performed in at least 
4 independent experiments. The expected ratios are indicated by the 
grey line. b Relative quantification of mutant and wildtype MYH7-
mRNA in M. soleus or myocardial tissue from HCM-patients. Quan-
tification was performed on RNA extracted from at least two pieces 
of tissue at least in duplicate analysis. Each dot represents a single 
quantification analysis. The asterisks indicate significant deviation 
from 50% (one way ANOVA; p < 0.0001)
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Allelic imbalance of the MYH7 gene in non‑HCM 
individuals
To test whether the MYH7 alleles are generally expressed 
imbalanced and that this is not specific for HCM patients, we 
analyzed cardiac tissue from non-HCM control individuals. 
Three different single nucleotide polymorphisms within the 
MYH7 gene were used for allelic discrimination.
Specific qPCR and restriction digest analyses were estab-
lished for each SNP and validated using standard plasmid 
mixtures as described for the HCM-mutations (Fig. 2a). For 
each individual, three independent RNA extractions were 
performed and analyzed as described for the HCM-patients. 
Most interestingly, we determined a statistically significant 
deviation from the 50:50 allelic expression ratio in four out 
of 11 non-HCM donors (Fig. 2b). For three control individu-
als we determined up to 60% of the variant allele, and one 
control individual showed a low fraction of the variant allele 
of on average 5.5% (Table 2). Therefore, the allelic expres-
sion ranges from equal to almost exclusively one allele. 
Nevertheless, both alleles were expressed in all individuals.
Discussion
Allelic imbalance is a general feature of MYH7 mRNA 
expression
Several studies on HCM-patients have shown unequal 
expression of the mutant and wildtype alleles of β-myosin 
(MYH7) (Di Domenico et al. 2012; Nier et al. 1999; Tripathi 
et al. 2011; Witjas-Paalberends et al. 2013) and myosin bind-
ing protein (MYBPC3) (Helms et al. 2014) at mRNA and 
protein level. Also balanced allelic expression of the mutant 
and wildtype mRNA associated with imbalanced expres-
sion of mutant and wildtype protein have been reported 
(Helms et al. 2014). Clinically, the severity of HCM has 
been linked to the fraction of mutant protein (Jiang et al. 
2013; Tripathi et al. 2011) and to the degree of imbalance 
(Helms et al. 2014). In line with these findings our present 
study shows MYH7-allelic expression imbalance and balance 
in the HCM-patients, both at the mRNA and at the protein 
level. The allelic imbalance encompasses a broad range, 
from an almost exclusive expression of either the mutant or 
Table 4  Variants detected upon 
analysis of the MYH7 promoter, 
5′-UTR, 3′-UTR, exons, and 
flanking intron sequences
Patient Location Web Ref. HGVS nomenclature Effect Genotype
G741-1 Exon rs2069540 c.189C>T SNP Homozygous
Exon c.2221G>C Mutation Heterozygous
Exon rs3729830 c.5106G>A SNP Heterozygous
G741R-2 Exon rs2069540 c.189C>T SNP Heterozygous
Exon c.1095G>A SNP Heterozygous
Exon c.2221G>C Mutation Heterozygous
Exon rs7157716 c.2967T>C SNP Heterozygous
G741R-3 Exon rs2069540 c.189C>T SNP Homozygous
Exon c.2221G>C Mutation Heterozygous
Fig. 2  Relative quantification of the MYH7 alleles in myocardium of 
non-HCM control individuals using heterozygous single nucleotide 
polymorphisms. a Defined mixtures of synthetic plasmids encod-
ing for the wildtype and T63T (triangle) I989I (cross) or A1702A 
(open circle) variant, respectively were amplified by quantitative 
PCR and quantified densitometrically from allele specific restric-
tion digests. Quantifications were performed in at least four inde-
pendent experiments. The expected ratios are indicated by the grey 
line. b Relative quantification of MYH7-mRNA in myocardial tissue 
from 11 non-HCM control individuals carrying the variants T636T, 
I989I, and A1702A, respectively. Quantification was performed on 
RNA extracted from at least two pieces of tissue at least in duplicate 
analysis. Each dot represents a single quantification analysis. The 
asterisks indicate significant deviation from 50% (one way ANOVA; 
p < 0.0001)
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the wildtype allele, respectively, to a balanced expression of 
both alleles. However, allelic expression imbalance has also 
been shown for many different genes under healthy condi-
tions (Jeffries et al. 2016). In accordance, also non-HCM 
control individuals showed imbalanced expression of the 
MYH7-alleles. Next to only slight deviations from the 50:50 
ratio also a marked imbalance was detected. Our findings 
contradict the assumption that MYH7-missense mutations 
cannot be expressed imbalanced in HCM-patients at the 
mRNA or protein level (Helms et al. 2014). The authors 
assume, that only premature termination codons would cause 
allelic imbalance. In contrast, our study shows, in line with 
findings from other groups (Heap et al. 2009; McDaniell 
et al. 2010; Serre et al. 2008), that allelic imbalance is a 
common mechanism of gene expression; also under non-dis-
ease associated conditions. Therefore, our findings provide 
evidence that a general variation in MYH7-allelic expression 
exists and importantly, may also underlie at least part of the 
allelic imbalance experienced in HCM-patients.
At the mRNA-level, a marked allelic imbalance was only 
found in male individuals. However, in previous studies 
we have also determined ratios of 70/30 in a female patient 
(H29, Tripathi et al. 2011). Therefore, we assume that our 
cohort is not representative with regard to gender diversity. 
In addition, at the protein level both, male and female HCM-
patients show significant allelic imbalance.
It should be noted that we used the different SNPs in the 
non-HCM individuals only as indicators for the differen-
tial expression of the MYH7-alleles. These SNPs are very 
common (Table 3) and are also found in some of the HCM-
patients (Table 4). Since the allele specific expression levels 
vary largely between individuals with the same SNPs we do 
not assume that the examined SNPs dominate allelic imbal-
ance establishment. However, it seems likely that at least 
some SNPs may contribute significantly to regulation of the 
allelic expression of the MYH7-alleles.
Our results from donor individuals show for the first time, 
that allelic imbalance is an intrinsic, non-HCM-dependent 
feature of MYH7-gene expression. Under healthy condi-
tions—without disease causing mutations—the imbalanced 
allelic expression of genes will have no further effect on 
functional parameters. However, altered expression of vari-
ants that affect protein function or increase disease suscep-
tibility may exhibit severe effects on the metabolism, e.g. 
cardiomyocyte and thus cardiac function. Finally, this may 
increase the severity or occurrence of the respective disorder 
as shown for multiple sclerosis (Keshari et al. 2016), auto-
immune diseases (Ge et al. 2009), cancer (Chen et al. 2008; 
Wang et al. 2016) and HCM (Di Domenico et al. 2012; 
Helms et al. 2014; Tripathi et al. 2011). And vice-versa, 
in a mouse model of HCM, the targeted knock-down of the 
mutant allele has been shown to improve HCM-phenotype 
(Jiang et al. 2013). Therefore, next to the direct “poisoning” 
effect of the MYH7-mutations on β-MyHC function, the 
unequal expression of mutated and wildtype alleles may 
provide an essential player in HCM development (Brenner 
et al. 2014). Our results indicate that in patients with HCM-
mutations, the intrinsic MYH7-allelic imbalance may be one 
additional factor that affects disease progression.
Mutation dependent and independent mechanisms 
regulate unequal allelic expression of MYH7
In a previous study we have shown that the MYH7 alleles 
are expressed at different ratios in neighboring cells in the 
myocardium, causing a functional imbalance between these 
cells that may finally trigger the progression of myofibrillar 
and myocardial disarray and hypertrophy (Kraft et al. 2016). 
We assume that this cell-to-cell allelic imbalance is caused 
by independent, stochastic ON- and OFF-switching of each 
MYH7-allele, so-called bursts-of-transcription. However, the 
stochastic expression pattern should result in equal levels of 
each allele averaged over the multitude of cells analyzed in 
our tissue samples. Nevertheless, the average of all single 
cells in patients with the mutation R723G show a compa-
rable level of allelic imbalance as determined at the tissue 
level (Kraft et al. 2016). In consequence, additional mecha-
nisms must cause an average drift of the allelic expression 
towards one allele. Our present study did not address the 
exact mechanisms of allelic expression establishment. How-
ever, our findings allow to draw some conclusions that may 
provide deeper insights into such potential mechanisms.
Exemplary analysis of the promotor region in three 
patients and the 5′- and the 3′-UTR in 6 patients revealed 
no variant. Variants in these regions can affect mRNA- and 
protein levels by altering transcription factor- or miRNA-
binding, respectively. Based on the absence of variants in 
the analyzed patients with and without allelic imbalanced 
expression, we assume no influence on allelic expression 
regulation in these cases. Nevertheless, in other patients 
imbalance may be induced by variants in these regions.
The observation of unequal expression of the two MYH7-
alleles in non-HCM control individuals suggests that allelic 
imbalance of MYH7 is an intrinsic feature of this gene, 
which may be modulated by HCM-associated missense 
mutations. Interestingly, in most cases the relative fraction of 
mutant alleles seems to be comparable between patients with 
identical mutations as we have shown previously for related 
patients (I736T) and unrelated patients with presumably a 
common founder mutation (R723G) (Enjuto et al. 2000; 
Tripathi et al. 2011). Even though this may be explained 
by identical inherited - but mutation independent - regu-
latory motifs, we have hypothesized that also a mutation 
induced alteration of the mRNA turnover may cause this 
imbalance (Tripathi et al. 2011). In line with this hypothesis, 
here we found comparable allelic imbalance in three patients 
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unrelated to patients from previous studies: the patient with 
mutation V606M had 38% mutated mRNA in myocardial 
tissue, which is similar to the previously determined 28% 
mutated mRNA in M. soleus (Tripathi et al. 2011). In addi-
tion, patients with the mutations R719W and T1377M, 
respectively, show only a moderate increased expression of 
the mutant allele or a balanced expression of both alleles in 
this and previous studies (Helms et al. 2014; Tripathi et al. 
2011). This supports the assumption that the mutations may 
also directly influence the allelic expression (Tripathi et al. 
2011). E.g. we have preliminary evidence that the muta-
tion R723G alters mRNA secondary structure (unpublished 
data), indicating that mutations can influence the mRNA sta-
bility. In addition point mutations can act as a cis-regulatory 
variant for methylation, alter the affinity of RNA-binding 
proteins that affect recruitment of DNA-methylation com-
plexes or histone modifications (Zhang et al. 2009).
Next to mutation associated regulators, our results indi-
cate that also mutation independent factors influence the 
allelic expression. One of the three patients with the muta-
tion G741R has a significantly lower fraction of the mutant 
mRNA compared to the others. Analysis of the promotor and 
3′-UTR (Table 4) did not reveal any difference between the 
patients, indicating that here either intragenic or epigenetic 
factors may also affect the allelic expression of MYH7. Reg-
ulation of allelic expression biases have been assumed to be 
genetically determined (Pastinen 2010) and also epigeneti-
cally regulated (Tycko 2010). Especially the allele specific 
methylation (ASM) and allele specific transcription factor 
binding (ASTF) have been determined as potent cis-acting 
regulators of allelic imbalance (Jeffries et al. 2016; Nakaoka 
et al. 2016; Tycko 2010). The expression of the MYH7 gene 
is regulated by DNMT3a dependent methylation of the pro-
motor (Fang et al. 2016). Therefore, allele specific levels of 
methylation of the MYH7 promotor may also provide one 
mechanism for the establishment of allelic imbalance irre-
spective of the HCM mutations.
Taken together, our data indicate that the MYH7-alleles 
can be expressed imbalanced in healthy individuals, without 
causing cardiac pathologies. In patients with HCM-muta-
tions, this intrinsic imbalance may then be one factor that 
determines disease progression. However, most patients with 
identical mutations show comparable levels of allelic imbal-
ance. Therefore, in addition to the intrinsic allelic imbal-
ance, also mutation-associated regulators may determine the 
allelic expression.
Transcriptional and post‑transcriptional mechanisms 
induce allelic imbalance of mutant and wildtype 
β‑MyHC at the protein level
In six out of six HCM-patients from a previous study (Tri-
pathi et al. 2011) and in two out of five mutations in this 
study the allelic imbalance at the protein level is compa-
rable to the mRNA allelic imbalance. This in accordance 
with the assumption that “Protein Levels at Steady State Are 
Primarily Determined by mRNA Levels” (Liu et al. 2016). 
Therefore, we assume that in most cases the MYH7-allelic 
imbalance is induced prior to translation of the MYH7-gene 
and thus mRNA imbalance is paralleled by protein level 
imbalance.
Most interestingly, the missense mutations G741R and 
G716R show lower fractions of mutated protein as compared 
to the respective mutated mRNA fractions. The examined 
mutations are missense mutations that do not cause frame 
shifts. Therefore, mechanisms such as nonsense mediated 
decay are highly unlikely (Helms et al. 2014). The dispar-
ity of mRNA and protein levels can be linked to different 
mechanisms as reviewed in (Maier et al. 2009): first, the 
RNA secondary structure can alter the translation efficacy. 
As stated above, we have preliminary evidence, that HCM-
mutations may alter the secondary structure of the mRNA. 
Future analyses will address a possible effect of these spe-
cific mutations on the secondary structure. Second, regula-
tory RNAs such as miRNAs may inhibit mRNA translation. 
However, analysis of the 5′- and the 3′-UTR of the patients 
revealed no variant, therefore an aberrant miRNA-binding 
seems rather unlikely. Third, the ribosomal density can 
regulate the translation efficiency. Determinants of riboso-
mal density are located in the 5′-UTR (Dvir et al. 2013), 
which contains no variants in the analyzed patients. There-
fore, the ribosomal density will most likely not affect the 
protein levels. Forth, a reduced protein half-life can lead 
to reduced levels of protein. The HCM-mutations G716R 
and G741R could lead to proteins that are degraded faster 
than the wildtype proteins. This would lead to the observed 
decreased mutant:wildtype ratio at the protein as compared 
to the mRNA level. Future experiments will have to show, 
whether the half-life of the β-MyHC protein is shortened by 
the mutations G716R and G741R. Last but not least, alterna-
tive splicing resulting in non-functional proteins may have 
caused the reduced mutant protein levels as compared to 
the mRNA. For myosin binding protein C (MYBPC3) muta-
tions, differential splicing of wildtype and mutant mRNA 
is an important mechanism that affects protein level imbal-
ance (Helms et al. 2014). For MYH7 mutations splice effects 
have not been experimentally determined so far, however, 
bioinformatically predicted (Tripathi et al. 2011). Also for 
the base substitution c.2146G>A leading to the mutation 
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G716R the generation of an alternative splice site, however 
with a comparable activity score as the original splice site, 
is predicted (Desmet et al. 2009). Nevertheless, differen-
tial splicing may act as one mechanism underlying protein 
level allelic imbalance. Most interestingly, the three G741R 
patients with different fractions of mutant mRNA showed 
comparable fractions of mutant and wildtype protein for all 
three patients. Here a post-transcriptional mechanism seems 
to establish a constant mutant protein ratio, irrespective of 
the initial fraction of mutant mRNA. Further studies will 
have to clarify the post-transcriptional mechanisms that 
affect the expression of mutant and wildtype β-MyHC.
Conclusion
Our study provides evidence that the MYH7 alleles can be 
expressed balanced and highly imbalanced at the mRNA and 
at the protein level in both, HCM-patients and non-HCM 
controls. In non-HCM control individuals, the imbalanced 
expression will have no physiological impact. However, in 
HCM-patients one allele encodes for a functionally altered 
protein of the contractile apparatus. The influence of this 
alteration may increase with an increasing fraction of mutant 
protein. Our results suggest that diverse mechanisms must 
exist for the establishment of allelic imbalance not only 
between patients with different mutations but also between 
patients sharing identical HCM-mutations.
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